355 related articles for article (PubMed ID: 28698435)
1. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
2. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
3. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
5. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
6. Treating soft tissue sarcomas with adjuvant chemotherapy.
Patrikidou A; Domont J; Cioffi A; Le Cesne A
Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
8. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
9. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for adult soft tissue sarcoma.
Radaelli S; Stacchiotti S; Casali PG; Gronchi A
Expert Rev Anticancer Ther; 2014 Jun; 14(6):689-704. PubMed ID: 24555529
[TBL] [Abstract][Full Text] [Related]
11. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy in the management of soft tissue sarcomas.
Krikelis D; Judson I
Expert Rev Anticancer Ther; 2010 Feb; 10(2):249-60. PubMed ID: 20132000
[TBL] [Abstract][Full Text] [Related]
13. Treatment with trabectedin: should be indicated to all soft tissue sarcoma histotypes?
Grivas A; Trafalis DT; Thanopoulou E; Ziras NG; Athanasiou AE
J BUON; 2010; 15(4):791-3. PubMed ID: 21229647
[TBL] [Abstract][Full Text] [Related]
14. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
15. Current management options for liposarcoma and challenges for the future.
Kollár A; Benson C
Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
[TBL] [Abstract][Full Text] [Related]
16. Newer medical therapies for metastatic soft tissue sarcoma.
Tiwari A; Gupta VG; Bakhshi S
Expert Rev Anticancer Ther; 2017 Mar; 17(3):257-270. PubMed ID: 28103739
[TBL] [Abstract][Full Text] [Related]
17. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas.
Casali PG
Ann Oncol; 2012 Sep; 23 Suppl 10():x167-9. PubMed ID: 22987955
[TBL] [Abstract][Full Text] [Related]
18. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Van Tine BA; Trent JC
Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
[TBL] [Abstract][Full Text] [Related]
19. Histology-driven chemotherapy in soft tissue sarcomas.
Scurr M
Curr Treat Options Oncol; 2011 Mar; 12(1):32-45. PubMed ID: 21359911
[TBL] [Abstract][Full Text] [Related]
20. Contemporary management of metastatic soft tissue sarcoma.
Bui NQ; Wang DS; Hiniker SM
Curr Probl Cancer; 2019 Aug; 43(4):289-299. PubMed ID: 31248634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]